Add to a list

Inactive Instrument

NeuroVive Pharmaceutical AB Stock Swiss Exchange

Stocks

NVP

SE0002575340

Biotechnology & Medical Research

OTC Markets Traded

Latest news : NeuroVive Pharmaceutical AB

25-03-17	Calendar Monday, March 17	FW
25-03-17	Abliva has today the last trading day on Nasdaq Stockholm before delisting	FW
25-03-07	Pharming Group Unit's Ownership of Abliva Tops 97% After Takeover Offer Extension	MT
25-03-03	Abliva is delisted from Nasdaq Stockholm with the last trading day on March 17	FW
25-02-26	Alexander Breidenbach Proposed As Board Chairman	RE
25-02-25	Abliva Applies to Delist From Nasdaq Stockholm	MT
25-02-25	Abliva applies for delisting from Nasdaq Stockholm	FW
25-02-24	Abliva AB(OM:ABLI) dropped from OMX Nordic Small Cap Index	CI
25-02-24	Abliva AB(OM:ABLI) dropped from OMX Nordic All-Share Index	CI
25-02-21	Abliva reports small changes in earnings	FW
25-02-21	Abliva Proposes No Dividend For 2024	RE
25-02-21	Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
25-02-21	Pharming controls 92.7 percent of Abliva - intends to call for compulsory acquisition	FW

More news

Analysts' recommendations: NeuroVive Pharmaceutical AB

24-12-17	Affärsvärlden sees many indications that the takeover bid for Abliva will go through	FW
24-12-16	Abliva bid has attractive premium, high probability of success - Penser	FW
24-07-29	Abliva well positioned after positive results - Penser	FW
24-05-27	Penser: Abliva's Q1 in line with expectations - focus on upcoming interim analysis	FW
24-02-27	Penser: No surprises in Q4 from Abliva - costs expected to continue to rise	FW

More recommendations

Press Releases: NeuroVive Pharmaceutical AB

25-03-17	BioStock: Last trading day for Abliva - the company leaves Nasdaq Stockholm	AQ
25-03-03	Delisting of the shares of Abliva: last day of trading 17 March 2025	AQ
25-02-26	Notice of Extraordinary General Meeting in Abliva AB (publ)	AQ
25-02-25	Abliva applies for delisting and will convene an extraordinary general meeting	AQ
25-02-21	Abliva AB Year-End Report January – December 2024	AQ

More press releases

Managers and Directors: NeuroVive Pharmaceutical AB

Manager	Title	Age	Since
Catharina Jz Johansson DFI	Director of Finance/CFO	59	2014-01-09
Dag Nesse CTO	Chief Tech/Sci/R&D Officer	60	2023-01-31
Magnus Hansson CTO	Chief Tech/Sci/R&D Officer	50	2015-12-31

Director	Title	Age	Since
David Laskow-Pooley CHM	Chairman	72	2017-11-05
Jan Birger Fredrik Toernell BRD	Director/Board Member	66	2017-04-26
David Bejker BRD	Director/Board Member	51	2017-04-26

More insiders

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUROVIVE PHARMACEUTICAL AB	-.--%	-.--%	-	-	76M
ARGENX SE	+0.33%	+1.37%	+63.66%	+126.38%	55.63B
WUXI APPTEC CO., LTD.	+0.82%	+15.05%	+79.93%	+84.34%	52.25B
BIONTECH SE	+1.36%	+0.36%	-14.52%	-13.83%	23.07B
INSMED INCORPORATED	-1.04%	+7.91%	+3.91%	+417.68%	22.41B
WUXI BIOLOGICS (CAYMAN) INC.	-0.18%	+7.20%	+32.16%	-14.07%	17.32B
GENMAB A/S	-1.10%	+4.00%	+28.70%	-34.51%	15.94B
PHARMAESSENTIA CORPORATION	-3.35%	+8.96%	+132.20%	+290.18%	13.47B
EXELIXIS, INC.	+2.89%	+5.51%	+25.42%	+186.30%	13.77B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.31%	+0.53%	+28.62%	-	12.43B
Average	+0.10%	+4.86%	+42.23%	+130.31%	25.14B
Weighted average by Cap.	+0.26%	+5.21%	+48.48%	+122.31%

See all sector performances

Company Profile

Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!